Who we are
scleroderma.ai is a not-for-profit research project trying to determine if we can use artificial intelligence (AI) and computer vision technologies to early-diagnose Scleroderma.
Our team consists of internationally well-known scleroderma researchers, as well as technology entrepreneurs.
Scleroderma.ai is operated by Sclero AI Inc, a British Columbia, Canada company.
Our mission
We want to advance solutions that aid in the early detection of Scleroderma, enabling earlier treatment and better patient outcomes. We do this by leveraging artificial intelligence (AI) technology.
What are we building?
Patients with Scleroderma can often be recognized by changes in their faces and hands. We hypothesize that facial and hand features of Scleroderma patients are distinctive and can be detected by a trained AI system after processing a picture of a Scleroderma patient’s face and hands. This system could be used by family practitioners and internists, aiding them to increase suspicion of Scleroderma and refer patients in a timely manner.
